Most therapeutic approaches in immuno-oncology focus on targeting the adaptive immune system; innate immunity has only recently gathered momentum. One of the most potent receptors for activating innate immune cells such as natural killer cells and macrophages is CD16A. Addressing this target mimics the body’s natural defense against potential threats, resulting in a cascade of defence mechanisms. German biotech Affimed developed a versatile bispecific antibody technology platform, providing a cleverly engineered solution to activate CD16A and harness natural killer cells and macrophages against cancer. Here, Arndt Schottelius, CSO of Affimed, shares insights on unleashing the potential of the innate immune system.